Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell
I'm PortAI, I can summarize articles.
Wall Street Zen has downgraded Cellectis (NASDAQ:CLLS) from a "hold" to a "sell" rating. Barclays also reduced its price target for Cellectis from $5.00 to $4.00 while maintaining an "overweight" rating. Cellectis shares traded up 0.3% to $1.53, with a market cap of $84.77 million. The company reported a quarterly EPS of ($0.18), missing estimates, and anticipates a fiscal year EPS of -0.46. Institutional investors hold 63.90% of the stock, indicating significant interest in the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Market Beat The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments